Airbnb, Inc. (NASDAQ:ABNB) reported strong earnings and sales results for its fourth quarter and issued strong Q1 sales forecast.
Airbnb reported fourth-quarter revenue of $1.9 billion, up 24% year-over-year. The company reported fourth-quarter earnings per share of 48 cents.
Airbnb is guiding for first-quarter revenue to come in a range of $1.75 billion to $1.82 billion, which is above the Street estimate of $1.69 billion.
Airbnb shares gained 3.8% to close at $120.87 on Tuesday and added 8.6% in today’s pre-market trading.
These analysts made changes to their price targets on Airbnb following the release of results.
- Keybanc raised the price target on Airbnb from 142 to $144. Keybanc analyst Justin Patterson maintained an Overweight rating.
- Needham boosted the price target on Airbnb from $150 to $155. Needham analyst Bernie McTernan maintained a Buy rating.
- Credit Suisse increased the price target on Airbnb from $154 to $160. Credit Suisse analyst Stephen Ju maintained a Neutral rating.
- Piper Sandler boosted the price target on Airbnb from $110 to $131. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral.
- Barclays increased the price target on Airbnb from $105 to $128. Barclays analyst Mario Lu maintained an Equal-Weight rating.
- UBS raised the price target on Airbnb from $114 to $130. UBS analyst Lloyd Walmsley maintained a Neutral rating.
- Baird boosted the price target on Airbnb from $100 to $125. Baird analyst Colin Sebastian maintained the stock with a Neutral rating.
- Mizuho increased the price target on Airbnb from $110 to $125. Mizuho analyst James Lee maintained the stock with a Neutral rating.
- Wells Fargo boosted the price target on Airbnb from $130 to $165. Wells Fargo analyst Brian Fitzgerald maintained the stock with an Overweight rating.
- Cowen & Co. raised the price target on Airbnb from $135 to $145. Cowen & Co. analyst Kevin Kopelman maintained the stock with an Outperform rating.
- Goldman Sachs raised the price target on Airbnb from $87 to $98. Goldman Sachs analyst Eric Sheridan maintained the stock with a Sell rating.
Read More: $6M Bet On RxSight? Check Out These 3 Stocks Insiders Are Buying
